Gennex Laboratories Limited

GENNEX6

INE509C01026

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 05:43:24 2024-06-10 EDT			5-day change	1st Jan Change
16 ^INR	+0.44%		-5.72%	-4.82%

05-30	Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-14	Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Gennex Laboratories Limited Approves the Acceptance of Resignation of Rajesh Vankadara as Company Secretary & Compliance Officer

February 14, 2023 at 07:08 am

Gennex Laboratories Limited approved the acceptance of resignation of Mr. Rajesh Vankadara, as company secretary & Compliance officer of the Company, at its board meeting held on February 14, 2023.

Latest news about Gennex Laboratories Limited

Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	02-14	CI
Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director	02-01	CI
Gennex Laboratories Gets Good Manufacturing Practices Certificate from Indian Regulator	12-13	MT
Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd	12-01	CI
Gennex Laboratories Board to Consider Raising Funds Via Equity	11-29	MT
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Gennex Laboratories Gets Permission to Manufacture, Sell Fexofenadine, Minoxidil	23-08-10	MT
Gennex Laboratories Limited Obtains Approval of Additional Products from Drug Control Administration, Government of Telangana	23-08-09	CI
Gennex Laboratories Gets WHO-GMP Certification from Drug Control Administration, Government of Telangana	23-07-11	MT
Gennex Laboratories Arm Gets Drug Manufacturing License	23-06-01	MT
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-31	CI
Gennex Laboratories Limited Appoints Dinesh Kumar Kejriwal as Company Secretary & Compliance Officer	23-04-20	CI
Gennex Laboratories Limited completed the acquisition of 6.73% minority stake in Deccan Remedies Limited.	23-02-28	CI
Gennex Laboratories Limited Approves the Acceptance of Resignation of Rajesh Vankadara as Company Secretary & Compliance Officer	23-02-14	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023	23-02-07	CI
Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana	22-07-27	CI
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Gennex Laboratories Board OKs Up to $5.3 Million Rights Issue	22-04-06	MT
Gennex Laboratories Board to Consider Fundraising Via Debt or Equity Offering	22-03-28	MT
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI

Chart Gennex Laboratories Limited

Duration

Period

More charts

Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The Company has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company operates through the Pharmaceutical Products (Bulk Drugs) segment. The Company's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The Company has manufacturing facilities in India which cater to both domestic and international markets.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENNEX LABORATORIES LIMITED	-4.82%	43.39M
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.82%	248B
ROCHE HOLDING AG	-1.80%	219B
NOVARTIS AG	+10.85%	216B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B